文献速递核素与放射性配体治疗

神经内分泌肿瘤患者接受177Lu-DOTATATE肽受体放射性核素治疗次最大活度后的长期结局

Long-Term Outcomes of Submaximal Activities of Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in Neuroendocrine Tumor Patients.
PubMed 文献 · J Nucl Med · 2022-06-09

该回顾性研究纳入2000至2019年接受177Lu-DOTATATE肽受体放射性核素治疗(PRRT)的晚期高分化神经内分泌肿瘤(NET)患者,比较因非疾病原因未接受计划累积活度29.6 GBq(800 mCi)者与接受该活度者的疗效。结果显示,次最大活度组疾病控制率85% vs 对照组93%(P=0.011),中位无进展生存期23个月 vs 31个月(P=0.001),中位总生存期34个月 vs 60个月(P<0.0001),校正混杂因素后累积活度为无进展生存期和总生存期的独立预测因素。

要点

  • 次最大活度组疾病控制率85%,低于对照组的93%(P=0.011)。
  • 次最大活度组中位无进展生存期23个月,对照组31个月(P=0.001)。
  • 次最大活度组中位总生存期34个月,对照组60个月(P<0.0001)。

核心结论

  • 在接受177Lu-DOTATATE累积活度低于29.6 GBq的NET患者中,PRRT在肿瘤缓解和生存方面的疗效低于接受29.6 GBq的患者。

研究设计与样本

  • 回顾性纳入2000至2019年接受PRRT的晚期高分化NET患者,次最大活度组为未接受29.6 GBq且减量非疾病相关者130例,对照组为2000至2012年接受29.6 GBq者350例。

主要发现

  • 次最大活度组接受3.7-27.8 GBq,其中48%因骨髓毒性、23%因最大肾脏吸收剂量而减量。
  • 次最大活度组较对照组骨转移更多、体重指数和白蛋白水平更低、碱性磷酸酶水平更高、1级肿瘤更少。
  • 次最大活度组疾病控制率85% vs 对照组93%(P=0.011)。
  • 次最大活度组中位无进展生存期23个月(95%CI 21-26个月) vs 对照组31个月(95%CI 27-35个月)(P=0.001)。
  • 次最大活度组中位总生存期34个月(95%CI 28-40个月) vs 对照组60个月(95%CI 53-67个月)(P<0.0001);多变量Cox回归校正混杂因素后,累积活度为无进展生存期和总生存期的独立预测因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In the literature, up to 45% of neuroendocrine tumor (NET) patients who are treated with 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) do not receive the intended cumulative activity of 29.6 GBq (800 mCi). The aim of this study was to analyze the efficacy of submaximal activities of PRRT in patients who discontinued treatment for non-disease-related reasons. Methods: We retrospectively included patients with well-differentiated and advanced NETs who underwent PRRT from 2000 until 2019 and did not receive 29.6 GBq of 177Lu-DOTATATE. For comparison, we selected control NET patients who received the intended cumulative activity of 29.6 GBq of 177Lu-DOTATATE between 2000 and 2012. Primary outcomes were progression-free survival (PFS) and tumor response, and the secondary outcome was overall survival (OS). Results: In total, 243 patients received 3.7-27.8 GBq. In 130 patients, the submaximal activity was unrelated to disease (e.g., bone marrow and renal toxicity in 48% and maximal renal absorbed dose in 23%), and they were included. Patients receiving a reduced activity had more bone metastases, a lower body mass index and albumin level, a higher alkaline phosphatase level, and fewer grade 1 tumors than the 350 patients included in the control group. The disease control rate in the reduced-activity group was 85%, compared with 93% for the control group (P = 0.011). The median PFS (95% CI) was 23 mo (range, 21-26 mo) for the reduced-activity group and 31 mo (range, 27-35 mo) for the control group (P = 0.001), and the median OS (95% CI) was 34 mo (range, 28-40 mo) and 60 mo (range, 53-67 mo), respectively (P < 0.0001). With adjustment for relevant confounders in the multivariable Cox regression analyses, cumulative activity was an independent predictor of both PFS and OS. Conclusion: In NET patients treated with a cumulative activity of less than 29.6 GBq of 177Lu-DOTATATE, PRRT was less efficacious in tumor response and survival than in patients who received 29.6 GBq.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Minczeles NS, de Herder WW, Feelders RA, et al. Long-Term Outcomes of Submaximal Activities of Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in Neuroendocrine Tumor Patients. J Nucl Med. 2022. PMID: 35680417. doi:10.2967/jnumed.122.263856

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。